Huateng Pharma to Showcase PEG Derivatives and CDMO Capabilities at CPHI Milan 2026

September 26, 2026

MILAN, ITALY— Hunan Huateng Pharmaceutical Co., Ltd. will exhibit at CPHI Milan 2026, taking place October 6–8 at Fiera Milano, where the company will showcase its PEG derivatives, pharmaceutical intermediates, and CDMO capabilities for pharmaceutical and biopharmaceutical development.

At Stand 3H94, Huateng Pharma will present a portfolio of PEG products designed to support applications including bioconjugation, drug delivery, and pharmaceutical research. The portfolio covers both polydispersed and monodispersed PEGs, as well as linear PEGs, lipid PEGs, and multi-arm PEGs.

Featured PEG products include mPEG-pALD, HZ-PEG-HZ, DSPE-PEG, Y-shape PEG-NHS, 4-arm PEG-SH, 4-arm PEG-SG, and 8-arm PEG-Mal, alongside selected monodispersed PEG products such as mPEG36-NH2, OH-PEG8-OH, OH-PEG9-OH, N3-PEG11-NH2, N3-PEG3-COOH, and NH2-PEG3-OH.

Beyond PEG chemistry, Huateng Pharma will highlight its CDMO capabilities for pharmaceutical intermediates and specialty chemicals, supporting projects from route design and quality studies through process optimization, validation, and commercial production.

The company's exhibition portfolio also includes selected veterinary APIs, cosmetic ingredients, pharmaceutical intermediates, and fine chemicals, including products such as DHHB, Tetrahydrocurcumin, Pyridine, and Pyrimidine.

“We look forward to meeting pharmaceutical and biopharmaceutical professionals in Milan and discussing how our PEG chemistry and manufacturing capabilities can support their development and supply requirements,” said Sonia Lee, Head of Business Development at Hunan Huateng Pharmaceutical Co., Ltd. “CPHI Milan provides an opportunity for us to better understand the needs of international partners and explore practical opportunities for collaboration.”

Huateng Pharma's manufacturing approach is designed to support projects from research-scale development to larger-scale production, with both non-GMP and GMP capabilities. Its CDMO services are intended to provide continuity as projects move from laboratory development toward process optimization and manufacturing.

Visitors to CPHI Milan are welcome to meet with Huateng Pharma team at Stand 3H94 to discuss PEG derivatives, pharmaceutical intermediates, CDMO projects, and potential collaboration opportunities.

Event Details

  • Event: CPHI Milan 2026
  • Date: October 6–8, 2026
  • Venue: Fiera Milano, Milan, Italy
  • Booth: 3H94

About Hunan Huateng Pharmaceutical Co., Ltd.

Hunan Huateng Pharmaceutical Co., Ltd. specializes in the development and manufacturing of PEG derivatives, pharmaceutical intermediates, APIs, and specialty chemicals. The company supports customers across pharmaceutical and biopharmaceutical development, from research-scale requirements to larger-scale manufacturing, with capabilities covering PEG chemistry, process development, and CDMO services.

Media & Business Contact: